ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 9.90
-0.24 (-2.37%)
At close: May 12, 2026
ChemPartner PharmaTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,140 | 1,135 | 965.1 | 1,132 | 1,321 | 1,685 |
Other Revenue | - | - | 5.1 | 6.5 | 5.54 | 6.16 |
| 1,140 | 1,135 | 970.2 | 1,138 | 1,327 | 1,691 | |
Revenue Growth (YoY) | 14.37% | 16.96% | -14.77% | -14.19% | -21.54% | 14.11% |
Cost of Revenue | 828.09 | 810.03 | 768.13 | 859.37 | 999.55 | 1,158 |
Gross Profit | 312.05 | 324.69 | 202.07 | 279 | 327.04 | 532.22 |
Selling, General & Admin | 233.74 | 233.37 | 203.62 | 256.78 | 306.24 | 331.24 |
Research & Development | 63.25 | 59.84 | 59.55 | 77.47 | 92.28 | 124.65 |
Other Operating Expenses | -5.87 | -7.62 | 4.92 | 5.66 | 7.48 | 5.69 |
Operating Expenses | 291.13 | 285.6 | 299.33 | 344.57 | 422.6 | 466.91 |
Operating Income | 20.93 | 39.1 | -97.26 | -65.57 | -95.56 | 65.31 |
Interest Expense | - | - | -26.1 | -31.3 | -66.48 | -78.73 |
Interest & Investment Income | 10.21 | 12.15 | 22.25 | 14.79 | 1,403 | 14.72 |
Currency Exchange Gain (Loss) | - | - | 10.88 | 3.52 | 44.05 | -6.12 |
Other Non Operating Income (Expenses) | -43.13 | -38.37 | -1.05 | -2.41 | -3.5 | 1.11 |
EBT Excluding Unusual Items | -11.99 | 12.89 | -91.28 | -80.97 | 1,281 | -3.71 |
Impairment of Goodwill | - | - | -139.26 | -816.73 | -232.4 | -367.6 |
Gain (Loss) on Sale of Investments | -0.11 | - | -2.3 | -0.92 | -0.04 | 0.06 |
Gain (Loss) on Sale of Assets | -6.3 | -0.04 | 8.43 | -0 | -0.15 | -0.02 |
Asset Writedown | 1.66 | 3.17 | -21.49 | -50.45 | -312.89 | -5.67 |
Other Unusual Items | - | - | 14.25 | 9.3 | 8.85 | 15.91 |
Pretax Income | -16.75 | 16.01 | -231.64 | -939.77 | 744.72 | -361.03 |
Income Tax Expense | -5.65 | 2.46 | -5.13 | -22.83 | 366.34 | 41.07 |
Earnings From Continuing Operations | -11.1 | 13.55 | -226.51 | -916.94 | 378.38 | -402.1 |
Minority Interest in Earnings | -0.29 | -0.14 | 0.04 | 0.19 | 0.21 | -0.15 |
Net Income | -11.39 | 13.41 | -226.47 | -916.75 | 378.59 | -402.25 |
Net Income to Common | -11.39 | 13.41 | -226.47 | -916.75 | 378.59 | -402.25 |
Shares Outstanding (Basic) | 394 | 447 | 503 | 498 | 498 | 497 |
Shares Outstanding (Diluted) | 394 | 447 | 503 | 498 | 498 | 497 |
Shares Change (YoY) | -27.22% | -11.17% | 1.01% | 0.02% | 0.31% | -0.64% |
EPS (Basic) | -0.03 | 0.03 | -0.45 | -1.84 | 0.76 | -0.81 |
EPS (Diluted) | -0.03 | 0.03 | -0.45 | -1.84 | 0.76 | -0.81 |
Free Cash Flow | 153.66 | 128.03 | 98.96 | -50.3 | -73.74 | 92.22 |
Free Cash Flow Per Share | 0.39 | 0.29 | 0.20 | -0.10 | -0.15 | 0.19 |
Gross Margin | 27.37% | 28.62% | 20.83% | 24.51% | 24.65% | 31.48% |
Operating Margin | 1.84% | 3.45% | -10.03% | -5.76% | -7.20% | 3.86% |
Profit Margin | -1.00% | 1.18% | -23.34% | -80.53% | 28.54% | -23.79% |
Free Cash Flow Margin | 13.48% | 11.28% | 10.20% | -4.42% | -5.56% | 5.46% |
EBITDA | 71.52 | 91.14 | -39.39 | -2.48 | 14.67 | 176.97 |
EBITDA Margin | 6.27% | 8.03% | -4.06% | -0.22% | 1.10% | 10.47% |
D&A For EBITDA | 50.59 | 52.05 | 57.87 | 63.1 | 110.23 | 111.66 |
EBIT | 20.93 | 39.1 | -97.26 | -65.57 | -95.56 | 65.31 |
EBIT Margin | 1.84% | 3.45% | -10.02% | -5.76% | -7.20% | 3.86% |
Effective Tax Rate | - | 15.36% | - | - | 49.19% | - |
Revenue as Reported | - | - | 970.2 | 1,138 | 1,327 | 1,691 |
Advertising Expenses | - | - | 0.47 | 0.73 | 0.68 | 0.76 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.